Skip to main content

Table 3 Microbiological evaluation at the end of the study treatment

From: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

Microbiological evaluation

TIS (n = 26)*

Placebo (n = 26)*

No pathogens

10 (38.5)

4 (15.4)

No sputum culture

5 (19.2)

7 (26.9)

Pseudomonas aeruginosa

1 (3.8)

6 (23.1)

Haemophilus influenzae

3 (11.5)

4 (15.4)

Staphylococcus aureus

2 (7.7)

2 (7.7)

Streptococcus pneumoniae

1 (3.8)

0

Other gram-negative pathogens

4 (15.4)

3 (11.5)

  1. Microbiological evaluation at the end of the study. Data are presented as n (%). *No significant differences were found between both groups. TIS Tobramycin Inhalation Solution